Cetirizine HCl
ApprovedSmall molecule
Mylan Pharmaceuticals IncCetirizine HCl is one of 10 small molecule programs targeting Hypoxemia. It is currently in Approved.
1
Indications
3
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Hypoxemia
#DrugCompanyPhaseTrials
1Esmeron
FFresenius Kabi Oncology Ltd.
Approved
Inomax
MMallinckrodt
Approved
Narcan
SScienture
Phase 3
Standard Treatment
Boehringer IngelheimPhase 3
Inhaled Prostacyclin
United TherapeuticsPhase 2
Cetirizine HCl
Mylan Pharmaceuticals IncApproved
Frespaciguat
Merck & Co.Phase 1
Inhaled Nitric Oxide
LLee's Pharmaceutical Limited
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Propranolol Pill
UUniversity of Missouri-Columbia
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cetirizine HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company